Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b5b921ecb9feed8fd280392d09b7276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_308ab73b3610373b586db1bb1be0dd08 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00589 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00547 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00559 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00452 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-0063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00333 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00619 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00351 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-04 |
filingDate |
2012-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2015-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8efa8ec05253610dcaeb1117cf27abf1 |
publicationDate |
2015-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8945108-B2 |
titleOfInvention |
Method of using vasoconstrictive agents during energy-based tissue therapy |
abstract |
A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy. |
priorityDate |
2006-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |